<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 16 Apr 2026 18:49:13 -0400--><rss version="2.0">
    <channel>
        <title>Alzamend Neuro, Inc. (ALZN) In The News</title>
        <link>https://ir.alzamend.com/news-events/articles/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/alzamend/files/theme/images/logo-sm.png</url>
                <title>Alzamend Neuro, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Q&A: Head coil aims to assist treatment for Alzheimer’s, bipolar, PTSD, depression]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.healio.com/news/neurology/20250326/qa-head-coil-aims-to-assist-treatment-for-alzheimers-bipolar-ptsd-depression</link>
                <pubDate>Tue, 15 Apr 25 00:00:00 -0400</pubDate>
                <guid>https://www.healio.com/news/neurology/20250326/qa-head-coil-aims-to-assist-treatment-for-alzheimers-bipolar-ptsd-depression</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Stephan Jackman of Alzamend Neuro: The CEO With a Two-Pronged Attack on Alzheimer’s and Mental Health Disorders]]></title>
                <description><![CDATA[]]></description>
                <link>https://meditechtoday.com/stephan-jackman-alzamend-neuro/</link>
                <pubDate>Wed, 06 Sep 23 00:00:00 -0400</pubDate>
                <guid>https://meditechtoday.com/stephan-jackman-alzamend-neuro/</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.biospace.com/article/releases/altasciences-completes-clinical-portion-of-alzamend-neuro-s-phase-iia-multiple-ascending-dose-clinical-trial-for-treatment-of-dementia-related-to-alzheimer-s/?utm_source=socialmedia</link>
                <pubDate>Tue, 18 Apr 23 00:00:00 -0400</pubDate>
                <guid>https://www.biospace.com/article/releases/altasciences-completes-clinical-portion-of-alzamend-neuro-s-phase-iia-multiple-ascending-dose-clinical-trial-for-treatment-of-dementia-related-to-alzheimer-s/?utm_source=socialmedia</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.benzinga.com/general/biotech/22/12/30211012/exclusive-alzamend-neuro-partners-with-stem-cell-institute-for-immunotherapy-vaccine-trial-for-de</link>
                <pubDate>Wed, 28 Dec 22 00:00:00 -0500</pubDate>
                <guid>https://www.benzinga.com/general/biotech/22/12/30211012/exclusive-alzamend-neuro-partners-with-stem-cell-institute-for-immunotherapy-vaccine-trial-for-de</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[CEO Stephan Jackman interviewed on Fox Business News]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.youtube.com/watch?v=67jLY2_AsSk&amp;amp;t=33s</link>
                <pubDate>Wed, 16 Nov 22 00:00:00 -0500</pubDate>
                <guid>https://www.youtube.com/watch?v=67jLY2_AsSk&amp;amp;t=33s</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro aiming to rapidly develop and market safe and effective treatments for Alzheimer's]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.proactiveinvestors.com/companies/news/990021/alzamend-neuro-aiming-to-rapidly-develop-and-market-safe-and-effective-treatments-for-alzheimer-s-990021.html?viewSource=TwitterUS</link>
                <pubDate>Fri, 12 Aug 22 00:00:00 -0400</pubDate>
                <guid>https://www.proactiveinvestors.com/companies/news/990021/alzamend-neuro-aiming-to-rapidly-develop-and-market-safe-and-effective-treatments-for-alzheimer-s-990021.html?viewSource=TwitterUS</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Stock Pops After Benzinga Exclusive On Cognition Therapeutics Alzheimer's Data]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.benzinga.com/markets/penny-stocks/22/08/28362844/alzamend-neuro-alzn-stock-pops-after-benzinga-exclusive-discusses-cognition-therapeutics-alz</link>
                <pubDate>Thu, 04 Aug 22 00:00:00 -0400</pubDate>
                <guid>https://www.benzinga.com/markets/penny-stocks/22/08/28362844/alzamend-neuro-alzn-stock-pops-after-benzinga-exclusive-discusses-cognition-therapeutics-alz</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[FDA provides guidance to Alzamend ahead of IND application for oral therapeutic]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.healio.com/news/psychiatry/20220721/fda-provides-guidance-to-alzamend-ahead-of-ind-application-for-oral-therapeutic</link>
                <pubDate>Thu, 21 Jul 22 00:00:00 -0400</pubDate>
                <guid>https://www.healio.com/news/psychiatry/20220721/fda-provides-guidance-to-alzamend-ahead-of-ind-application-for-oral-therapeutic</guid>
                                                                            </item>
            </channel>
</rss>